Tri-agonists of the GLP-1, GIP, and amylin receptors and uses thereof

TW202626702APending Publication Date: 2026-07-01NOVO NORDISK AS

View PDF 0 Cites 0 Cited by

Patent Information

Application Number: TW114146310
Authority / Receiving Office: TW · TW
Patent Type: Applications
Current Assignee / Owner
Priority Date: 2025-05-27
Filing Date: 2025-11-27
Publication Date: 2026-07-01

Application Information

Patent Timeline

27 May 2025

Priority

27 Nov 2025

Application

TW114146310

01 Jul 2026

Publication

TW202626702A

IPC: C07K14/575; A61K38/22; A61K38/26; A61K47/54; A61P3/04; A61P3/10; A61P9/00; C07K14/605; C07K19/00

Inventors: 克魯斯湯瑪斯; 勞賈斯佩 F

Get more patent work done with AI

Run novelty searches—or use them for FTO, design risk, drafting and technical problem-solving.

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗
IP MCP Servers
Connect trusted patent search and cited evidence to Claude, Cursor or your own AI workflow
↗

Patent Text Reader

Abstract

The present invention provides a GLP-1- / GIP- / amylin-receptor tri-agonist having a balanced potency ratio across all three receptors and / or having improved pharmacokinetic properties. The invention also provides pharmaceutical compositions comprising such a GLP-1- / GIP- / amylin-receptor tri-agonist as well as their use as a medicament for the treatment of subjects with overweight, obesity and associated co-morbidity.

Need to check novelty before this filing date? Find Prior Art